North America GLP-1 Receptor Agonist Market Report Scope & Overview:

North America GLP-1 Receptor Agonist Market was valued at USD 27.27 Billion in 2025 and is expected to reach USD 88.55 Billion by 2035, growing at a CAGR of 12.50% from 2026-2035.

The North America GLP-1 Receptor Agonist market will experience growth due to the increase in obesity and prevalence of type 2 diabetes, the expansion in payer coverage for incretin therapies, and continuous product differentiation within the semaglutide and tirzepatide classes. The use of GLP-1 Receptor Agonists by employers and commercial insurers for obesity indications, along with the talks within Medicare for anti-obesity drug coverage, is increasing the patient pool beyond that of diabetes treatment. The manufacturers are increasing their regional fill-finish capabilities to overcome the shortage issues faced in 2023-2024, while the oral products are trying to cater to the patients who do not like injections.

⮞The U.S. Centers for Medicare & Medicaid Services reported that national health expenditure growth accelerated through 2025 partly on prescription drug spending tied to GLP-1 therapies, underscoring the category’s outsized budget impact across North American payers. North America held approximately 45.00% share of the overall GLP-1 Receptor Agonist Market in 2025, while Asia Pacific is forecast to post the fastest regional CAGR of 26.50% from 2026-2035.

U.S. GLP-1 Receptor Agonist Market Outlook

U.S. GLP-1 Receptor Agonist Market was valued at USD 24.54 Billion in 2025 and is expected to reach USD 76.22 Billion by 2035, growing at a CAGR of 12.00% from 2026-2035.

The U.S. GLP-1 Receptor Agonist Market is advancing as obesity medicine becomes a mainstream primary-care specialty rather than a niche endocrinology service. Expanded prior-authorization pathways at large pharmacy benefit managers, growing employer willingness to cover anti-obesity medications, and continued direct-to-consumer marketing by manufacturers are each enlarging the treated population. Novo Nordisk and Eli Lilly continue to add fill-finish lines domestically to meet pen and vial demand, while new entrants are advancing oral and longer-acting candidates through late-stage trials. Hospital systems are also building dedicated weight-management clinics that route patients toward GLP-1 therapy, reinforcing volume growth even as list-price and rebate negotiations intensify between manufacturers and payers across the country.

⮞CMS confirmed in 2025 that it would not finalize broad Medicare Part D coverage of anti-obesity medications for the 2026 plan year, leaving commercial insurance and self-pay channels as the primary near-term growth drivers for U.S. demand. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

North America GLP-1 Receptor Agonist Market Segment Analysis

• By Product, Ozempic dominates the North America GLP-1 Receptor Agonist Market with 34.10% share in 2025; Zepbound is expected to grow at the fastest CAGR of 21.40% from 2026–2035.

• By Application, Type 2 Diabetes Mellitus dominates the North America GLP-1 Receptor Agonist Market with 48.30% share in 2025; Obesity is expected to grow at the fastest CAGR of 19.80% from 2026–2035.

• By Route of Administration, Parenteral dominates the North America GLP-1 Receptor Agonist Market with 65.40% share in 2025; Oral is expected to grow at the fastest CAGR of 19.90% from 2026–2035.

• By Distribution Channel, Retail Pharmacies dominate the North America GLP-1 Receptor Agonist Market with 44.20% share in 2025; Online Pharmacies are expected to grow at the fastest CAGR of 21.30% from 2026–2035.

By Product, Ozempic Dominates the North America GLP-1 Receptor Agonist Market, Zepbound Grows Fastest

Ozempic retained the largest product share across North America in 2025, supported by its long-standing diabetes label, deep physician familiarity, and broad payer formulary placement built up over several reimbursement cycles since its initial launch. Novo Nordisk’s continued direct-to-patient affordability programs, pharmacy partnerships, and sustained manufacturing investment have kept the brand the default starting therapy for most newly diagnosed type 2 diabetes patients across the United States and Canada, reinforcing its lead even as newer tirzepatide-based competitors expand marketing and capacity across the region. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Zepbound is forecast to grow fastest through 2035 as Eli Lilly expands obesity-specific marketing, pursues additional cardiometabolic label expansions, and scales incretin manufacturing capacity across its Indiana and North Carolina sites, converting latent obesity demand into prescriptions faster than any other branded product in the region. Growing direct-to-consumer advertising, expanding commercial payer formulary placement, and rising physician comfort prescribing tirzepatide specifically for weight management are reinforcing this momentum across both the United States and Canada through the forecast period. Growing physician familiarity with incretin therapy and expanding payer formulary discussions are expected to sustain this trajectory through the remainder of the forecast period.

By Application, Type 2 Diabetes Mellitus Dominates the North America GLP-1 Receptor Agonist Market, Obesity Grows Fastest

Type 2 diabetes management remains the largest application given its decade-long reimbursement history, established clinical guidelines, and the sheer size of the diagnosed diabetic population across the United States and Canada, which keeps volumes concentrated in this indication even as obesity prescribing accelerates rapidly. Physician familiarity with incretin therapy as a glycemic-control tool, combined with long-standing payer formulary placement built over multiple reimbursement cycles, continues to anchor diabetes care as the dominant revenue contributor across the region’s hospital and primary-care prescribing channels. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Obesity is set to post the fastest growth as commercial payers, self-pay patients, and a widening set of employer plans fund anti-obesity therapy, supported by new cardiovascular outcome data that is strengthening clinical and reimbursement arguments for earlier, broader obesity treatment across the region. Growing direct-to-consumer marketing, expanding telehealth prescribing access, and rising public awareness of obesity as a treatable chronic condition are each accelerating patient conversion from diagnosis to active incretin therapy across both the United States and Canada. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

By Route of Administration, Parenteral Dominates the North America GLP-1 Receptor Agonist Market, Oral Grows Fastest

Injectable formulations continue to dominate because approved weekly pen devices carry the strongest efficacy data and the longest physician track record, making them the default prescribing choice for both diabetes and obesity indications across North American clinics. Established manufacturing scale, broad payer formulary coverage, and years of patient familiarity with self-administered weekly injections further reinforce the channel’s lead, even as oral alternatives gain clinical attention and marketing investment from competing manufacturers across the region’s primary-care and specialist prescribing networks. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Oral GLP-1 therapy is growing fastest as patients who are needle-averse or new to treatment increasingly choose tablet-based options, with Eli Lilly’s orforglipron development program and Novo Nordisk’s oral semaglutide expansion both targeting primary-care prescribers who want a simpler starting therapy. Lower per-dose manufacturing complexity, easier pharmacy distribution, and growing physician comfort recommending oral incretin therapy as a first step are expected to accelerate this shift across both diabetes and obesity patient populations through 2035. Growing physician familiarity with incretin therapy and expanding payer formulary discussions are expected to sustain this trajectory through the remainder of the forecast period.

By Distribution Channel, Retail Pharmacies Dominate the North America GLP-1 Receptor Agonist Market, Online Pharmacies Grow Fastest

Retail pharmacy chains remain the primary dispensing point given their dense footprint, established insurance billing relationships, and patient familiarity, making them the natural channel for both new and refill GLP-1 prescriptions across U.S. and Canadian neighborhoods. Long-standing pharmacy benefit manager contracts, broad geographic coverage across suburban and urban markets, and continued patient preference for in-person pharmacist consultation on injection technique keep this channel central to both diabetes and obesity prescription fulfillment across the region. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Online pharmacy and telehealth-linked fulfillment is growing fastest as direct-to-consumer platforms streamline prescribing, cash-pay pricing, and home delivery, appealing particularly to self-pay obesity patients who want to avoid in-person clinic visits and faster access to therapy. Expanding telehealth-enabled prescribing networks, growing patient comfort with digital health platforms, and manufacturer-backed direct ordering programs are all reinforcing this channel’s rapid growth across both the United States and Canada through the forecast period. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as manufacturers and payers continue adjusting coverage and capacity to shifting incretin therapy demand.

Regional Analysis

U.S. GLP-1 Receptor Agonist Market Insights

The U.S. dominated the North America GLP-1 Receptor Agonist Market with the highest revenue share of about 89.63% in 2025, supported by the largest base of diagnosed diabetes and obesity patients in the region, dense commercial insurance coverage, and the concentration of manufacturer headquarters and fill-finish capacity within the country. The presence of major health systems, a mature pharmacy benefit manager infrastructure, and continuous direct-to-consumer marketing by Novo Nordisk and Eli Lilly keep the United States the primary revenue engine for the regional market across both diabetes and obesity applications.

Growing employer coverage of anti-obesity medication, expanding telehealth prescribing networks, and rising investment in dedicated weight-management clinics across major metropolitan markets continue to reinforce U.S. dominance within North America. Ongoing manufacturing capacity expansion at domestic fill-finish sites is further easing the supply constraints that limited volume growth through 2023-2024, allowing deferred demand across both diabetes and obesity indications to convert into sustained prescription growth through 2035. Continued investment in local commercial infrastructure and distribution is expected to reinforce this pattern through 2035 as patient volumes and payer negotiations evolve across the market.

Canada GLP-1 Receptor Agonist Market Insights

The Canada segment is expected to grow at the fastest CAGR of about 16.28% from 2026–2035, facilitated by Health Canada’s expanding approvals for obesity-indicated products and growing provincial drug plan discussions on incretin therapy reimbursement. Rising obesity prevalence, increasing private insurance coverage of anti-obesity medication, and growing physician referral pathways into specialized weight-management programs are accelerating incretin therapy adoption across Canadian provinces, narrowing the per-capita treatment gap with the United States over the forecast period. Growing physician familiarity with incretin therapy and expanding payer formulary discussions are expected to sustain this trajectory through the remainder of the forecast period.

Moreover, continued investment by Novo Nordisk and Eli Lilly in Canadian commercial infrastructure, combined with growing public awareness campaigns around obesity as a chronic disease, is supporting faster patient conversion from diagnosis to active therapy. Expanding private and employer-sponsored drug plan coverage across Ontario, Quebec, and British Columbia is expected to further reinforce Canada’s above-regional growth rate through 2035, even as public reimbursement for obesity indications remains more limited than in diabetes care. Rising patient awareness and continued manufacturer marketing investment are expected to reinforce this trend across the market through 2035.

Market Dynamics

Growth Drivers: Rising obesity and type 2 diabetes prevalence across the United States and Canada is increasing demand for incretin-based therapy.

Obesity and type 2 diabetes prevalence continue to climb across North America, pushing payers and employers to expand formulary coverage for GLP-1 therapy. Growing clinical evidence tying incretin therapy to cardiovascular risk reduction is reinforcing physician confidence in prescribing beyond glycemic control alone, while direct-to-consumer advertising keeps patient awareness and self-referral rates elevated. Manufacturer capacity expansions across U.S. and Canadian sites are also reducing the supply constraints that limited volume growth in 2023 and 2024, allowing demand that had been deferred during shortage periods to convert into new prescriptions across both diabetes and obesity segments.

Restraints: High list prices and inconsistent payer coverage for obesity indications are limiting broader patient access.

The list price of branded GLP-1 medications remains one of the biggest barriers to access, particularly in obesity conditions where Medicare Part D coverage is not yet clear and many commercial insurance plans have stringent prior authorization policies. The self-pay patient is faced with high monthly prices, which limit adherence, and the introduction of compounded options, which now face more rigorous regulatory scrutiny, mirrors the affordability problem created by branded prices. The rebate negotiations between manufacturers and pharmacy benefit managers create yet another level of price uncertainty, making volume prediction difficult for both payers and prescribers in the region.

Opportunities: Expansion into obesity-adjacent cardiometabolic indications and oral formulations creates new growth avenues.

The label extensions in the areas of heart failure, chronic kidney disease, and many others are expanding the applications of incretin therapies much further than diabetes and obesity alone. Late stage oral drugs under development are expected to reduce the barrier to treatment in people who dislike injection-based drug delivery, leading to a larger pool of patients from the primary care setting that could benefit from the therapy. Investments being made into increasing manufacturing capability and the entry of biosimilars as well as the next generation of incretins would also be reducing pressures on cost going forward.

North America GLP-1 Receptor Agonist Market Key Players are:

• Novo Nordisk A/S

• Eli Lilly and Company

• Pfizer Inc.

• Amgen Inc.

• AstraZeneca plc

• Merck & Co., Inc.

• Sanofi S.A.

• Boehringer Ingelheim International GmbH

• Teva Pharmaceutical Industries Ltd.

• Viking Therapeutics, Inc.

• Structure Therapeutics Inc.

• Altimmune, Inc.

• Zealand Pharma A/S

• CVS Health Corporation

• UnitedHealth Group Incorporated

• Walgreens Boots Alliance, Inc.

• Hims & Hers Health, Inc.

• McKesson Corporation

• Cencora, Inc.

• Roche Holding AG

North America GLP-1 Receptor Agonist Market Report Scope: